Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Yorker scores points off FDA’s Galson

Executive Summary

Acting CDER Director Steven Galson, MD, is the subject of a question in a tongue-in-cheek quiz by Paul Slansky in The New Yorker Aug. 30 focusing on the Bush Administration. The description matched to Galson's name: "the federal drug official who rejected the 23-4 recommendation of an advisory panel and refused to allow a morning-after birth-control pill to be sold over the counter" (1"The Pink Sheet" May 10, 2004, p. 6)...

You may also be interested in...



Plan B “Not Approvable” Decision Puts FDA, CDER Director In Hot Seat

FDA's "not approvable" decision for Barr Labs' emergency contraceptive Plan B over-the-counter switch puts the agency back in the spotlight of presidential campaign politics

Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044615

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel